Improving Diagnostic Sensitivity of Chronic Pulmonary Aspergillosis Using Species‐Specific IgG
Mycoses · 2025
DOI: 10.1111/myc.70107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2025. Verfasst von Inderpaul Singh Sehgal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Immunoglobulin G, Antibodies, Fungal, Pulmonary Aspergillosis, Aspergillus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Postgraduate Institute of Medical Education and Research, Chandigarh.
Abstract (Originalsprache)
Background
Chronic pulmonary aspergillosis (CPA) is most commonly caused by Aspergillus fumigatus (AF‐CPA). Serum A. fumigatus ‐IgG, a pivotal investigation for diagnosing CPA, misses 10%–15% of CPA cases. We aimed to determine whether measuring serum IgG against non‐fumigatus Aspergillus species enhances the serodiagnosis of CPA.
Methods
We prospectively enrolled consecutive, treatment‐naïve adults with CPA. The diagnosis of CPA was made using the ESCMID‐ERS criteria. Serum IgG against Aspergillus fumigatus , Aspergillus flavus , Aspergillus niger and Aspergillus terreus (cut‐off, 27 mgA/L) was measured by fluorescent enzyme immunoassay. Non‐fumigatus‐CPA (NF‐CPA) was defined when non‐fumigatus species‐specific IgG titres exceeded A. fumigatus ‐IgG by ≥ 25%. The primary objective was to evaluate the incremental diagnostic yield of non‐fumigatus species‐specific IgG for identifying CPA cases missed by A. fumigatus ‐IgG. The secondary outcome was to compare clinical features and treatment outcomes of AF‐CPA and NF‐CPA.
Results
Among 279 patients (mean age 45.7 ± 14.8 years, 64% male), seropositivity was 95.3% for A. fumigatus , 70.6% for A. flavus , 56.6% for A. niger and 30.5% for A. terreus . The addition of non‐fumigatus‐IgG increased serologic yield by 61%. NF‐CPA was diagnosed in 14% (39/279), with A. fumigatus ‐IgG alone missing 25.6% of these cases. Treatment outcomes at six ( n = 228) and 12 ( n = 222) months were similar between AF‐CPA and NF‐CPA groups, although the percentage reduction in serum A. fumigatus ‐IgG was significantly greater in AF‐CPA.
Conclusions
Incorporating non‐fumigatus Aspergillus ‐IgG enhances the serodiagnosis of CPA. However, treatment outcomes are similar in patients with AF‐CPA and NF‐CPA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Doodhadhari Burfani Hospital, Haridwar, India.
ORCID-Profile: Inderpaul Singh Sehgal, Ritesh Agarwal, Valliappan Muthu, Mandeep Garg, Arunaloke Chakrabarti
Förderung
- Postgraduate Institute of Medical Education and Research, Chandigarh
Zitieren
APA
Sehgal, I. S., Agarwal, R., Muthu, V., Dhooria, S., Prasad, K. T., Rudramurthy, S. M., Aggarwal, A. N., Garg, M., & Chakrabarti, A. (2025). Improving Diagnostic Sensitivity of Chronic Pulmonary Aspergillosis Using Species‐Specific IgG. Mycoses. https://doi.org/10.1111/myc.70107
Vancouver
Sehgal IS, Agarwal R, Muthu V, Dhooria S, Prasad KT, Rudramurthy SM, et al. Improving Diagnostic Sensitivity of Chronic Pulmonary Aspergillosis Using Species‐Specific IgG. Mycoses. 2025. doi:10.1111/myc.70107
BibTeX
@article{Sehgal2025,
author = {Sehgal, Inderpaul Singh and Agarwal, Ritesh and Muthu, Valliappan and Dhooria, Sahajal and Prasad, Kuruswamy Thurai and Rudramurthy, Shivaprakash M and Aggarwal, Ashutosh Nath and Garg, Mandeep and Chakrabarti, Arunaloke},
title = {Improving Diagnostic Sensitivity of Chronic Pulmonary Aspergillosis Using Species‐Specific IgG},
journal = {Mycoses},
year = {2025},
doi = {10.1111/myc.70107}
}
EUVIMED